The Clinical Core has characterized, followed and provided subjects and data, and has collected and banked biological specimens that have contributed to much research progress in the past 25 years in areas such as early and accurate diagnosis of AD, tracking the course of dementia, and testing new treatment approaches for AD.
The Specific Aims are: (1) Maintain and follow a panel of 400 well characterized English-speaking subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's Disease with Dementia (FDD), Mild Cognitive Impairment (MCI), and age- and education-matched healthy control subjects. (2) Maintain and follow a panel of 100 well characterized Spanish and English-speaking Hispanic subjects with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's Disease with Dementia (PDD), Mild Cognitive Impairment (MCI), and age- and education-matched healthy control subjects through our Hispanic Initiative. (3) Maintain a high autopsy rate (i.e., greater than 70%). (4) Perform annual detailed and standardized nursing, neurological, and neuropsychological evaluations of all subjects. (5) Maintain and augment banks of plasma, DNA, and CSF from subjects with AD, MCI, and healthy controls. (6) Share clinical data with the National Alzheimer's Disease Data Coordinating Center (NACC) Uniform Data Set (UDS) and with investigators performing other multi-center analyses of clinical data. (7) Participate in projects with other ADCs (e.g., NACC), in ADNI, and in multi-center therapeutic drug trials for AD. (8) Refine and evaluate clinical and neuropsychological assessment procedures for accurate identification of MCI and the transition to AD in very mildly impaired subjects. (9) Refine and evaluate clinical, neuropsychological, and laboratory assessment procedures for the accurate differentiation of AD from DLB, PDD, Frontotemporal dementia (FTD), and other dementing disorders. (10) Coordinate activities such as autopsy procurement and education with other Cores.

Public Health Relevance

AD affects millions of Americans with its risk growing exponentially with age. The AD Centers Program fosters research related to AD and non-AD dementias. The ADRC will enhance the performance of innovative research on AD and related topics, including research that may lead to potential disease modifying therapies or behavioral treatments. It will provide an environment and core resources to enhance research, foster professional and community training, and coordinate interdisciplinary research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-27
Application #
8051773
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
27
Fiscal Year
2010
Total Cost
$956,997
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251
Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058
Reas, Emilie T; Hagler Jr, Donald J; White, Nathan S et al. (2018) Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage Clin 20:883-891
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307

Showing the most recent 10 out of 914 publications